Newsletters
Melanoma gene expression test results compared against actual patient outcomes
July 2020
myPath® Melanoma demonstrates high level of diagnostic accuracy in uncertain cases
ASCO published recommendations on germline and somatic testing of ovarian cancer
May 2020
A new, evidence-based guideline released by the American Society of Clinical Oncology (ASCO) provides recommendations on genetic and tumor testing
Meta-analysis demonstrates significantly improved patient outcomes in major depressive disorder (MDD)
May 2020
GeneSight® cohort outperforms treatment-as-usual (TAU) cohort in every endpoint
2020 Newsletters
NCCN® prostate cancer guidelines say tumor-based molecular testing is appropriate for intermediate and high-risk disease
April 2020
Updated prostate cancer guidelines double the number of risk categories considered appropriate for molecular-based testing.
ASCO issued evidence-based guidelines for molecular biomarkers in localized prostate cancer
April 2020
The guidelines include recommendations regarding the clinical use and indications of certain prostate cancer biomarkers.
Advancing precision medicine for pancreatic cancer patients, Myriad obtains expanded BRACAnalysis CDx® indication
Feb 2020
The U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx as a companion diagnostic test to Lynparza® (olaparib), a PARP inhibitor.
GeneSight test significantly improved outcomes in depressed patients using 6-item Hamilton Scale
Jan 2020
Patients who received the GeneSight test had significantly improved clinical outcomes by week 8 (HAM-D6)
American College of Rheumatology (ACR) includes Vectra® in their new recommendations on disease activity measures
Jan 2020
Evaluation of its performance and feasibility results in Vectra meeting standards for regular use in clinical settings
2019 Newsletters
NCCN® expands testing criteria in Clinical Practice Guideline; Elevates importance of pancreatic cancer testing
Dec 2019
Testing criteria for high penetrance genes moves beyond BRCA1/2; Simplifies decision process
New study demonstrates patients with MDD taking antidepressants with gene-drug interactions benefit from GeneSight
Dec 2019
Published online in Journal of Clinical Psychiatry, Thase et al. assessed patients who entered the GUIDED study on medications with predicted gene-drug interactions
Dermatopathology experts publishing in SKIN provide guidance for the appropriate use of diagnostic gene expression profiling (GEP) in melanoma
Oct 2019
In their guidance, myPath® Melanoma earned their highest recommendation, “A-strength,” for a clinical scenario which mirrors myPath’s intended use.
How does Prolaris® improve health outcomes?
Sep 2019
Active surveillance (AS) is appropriate for patients with low-risk prostate cancer.
EndoPredict® accurately estimates absolute chemotherapy benefit at 10 years
Aug 2019
Data published in the ASCO Journal of Precision Oncology further demonstrates EndoPredict’s ability to accurately predict absolute chemotherapy benefit
Kroger Health and Myriad Genetics launch pilot to improve treatment of depression
July 2019
GeneSight® pharmacogenomic test now available to Kroger Prescription Plan members
New data demonstrate EndoPredict® breast cancer prognostic test’s ability to predict chemotherapy benefit and identify patients who can safely forgo extended endocrine therapy
June 2019
Findings promote reduction in overtreatment in ER+/HER2- breast cancer patients
Weighing Clinical and Patient Experience with Hereditary Pan-Cancer Panel Testing
May 2019
Among patients who carried a pathogenic variant (12%), one third of these clinically relevant results were not suspected upon pretest expert assessment
Medicare Issues Favorable Decision for myPath® Melanoma
April 2019
Diagnostic test drives reduction in overtreatment by providing definitive diagnosis for suspicious skin lesion biopsies
NCCN® elevates its prostate cancer germline testing reference to RECOMMENDED for all risk groups with qualification for Very Low, Low and Intermediate
March 2019
The National Comprehensive Cancer Network (NCCN) recently updated its Prostate Cancer Guidelines
Medicare coverage criteria updates align with NCCN® 2019 Guideline for BRCA1/2 genetic testing
February 2019
Precision Medicine Videos
Intended Use Population for Hereditary Cancer Testing
Chain of Evidence for CU
Variant Classification
Advantages of Panel Testing
Product Info
